[
  {
    "ts": null,
    "headline": "Why AbbVie Stock Slumped Today",
    "summary": "An encouraging quarterly earnings report was dampened by a new demand from President Trump.",
    "url": "https://finnhub.io/api/news?id=c706880789d05abe004991e928f9b5539826bb96fa8c258d5c9e8ba04a6eb10a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753998712,
      "headline": "Why AbbVie Stock Slumped Today",
      "id": 136160928,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "An encouraging quarterly earnings report was dampened by a new demand from President Trump.",
      "url": "https://finnhub.io/api/news?id=c706880789d05abe004991e928f9b5539826bb96fa8c258d5c9e8ba04a6eb10a"
    }
  },
  {
    "ts": null,
    "headline": "Trump Talks Tough on Drug Prices but His Demands Have Softened",
    "summary": "The president threatened to “deploy every tool” in the administration’s arsenal if drug companies don’t cut certain prices by late September.",
    "url": "https://finnhub.io/api/news?id=abfd0cbc3bdf5cf7eec493e57c4c23222429aa6d3fbd91ae1cf65b8720b77b7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753997100,
      "headline": "Trump Talks Tough on Drug Prices but His Demands Have Softened",
      "id": 136160929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The president threatened to “deploy every tool” in the administration’s arsenal if drug companies don’t cut certain prices by late September.",
      "url": "https://finnhub.io/api/news?id=abfd0cbc3bdf5cf7eec493e57c4c23222429aa6d3fbd91ae1cf65b8720b77b7a"
    }
  },
  {
    "ts": null,
    "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
    "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753992991,
      "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
      "id": 136160870,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Fall Late Afternoon",
    "summary": "Health care stocks fell late Thursday afternoon, with the NYSE Health Care Index declining 2% and th",
    "url": "https://finnhub.io/api/news?id=cc3fac7f2a3bf3393f948926a780b3ce8edcb8ca0ce6655fad02581f260210b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753991782,
      "headline": "Sector Update: Health Care Stocks Fall Late Afternoon",
      "id": 136160931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Health care stocks fell late Thursday afternoon, with the NYSE Health Care Index declining 2% and th",
      "url": "https://finnhub.io/api/news?id=cc3fac7f2a3bf3393f948926a780b3ce8edcb8ca0ce6655fad02581f260210b3"
    }
  },
  {
    "ts": null,
    "headline": "CoreWeave, Arm Holdings, AbbVie: Trending Tickers",
    "summary": "CoreWeave (CRWV) stock is in focus after Citigroup upgraded it to Buy and Morgan Stanley lifted its price target. Arm Holdings (ARM) stock is under pressure after the company issued a lower-than-expected profit outlook. AbbVie (ABBV) raised its full-year profit forecast and is facing pressure from President Trump over drug prices. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=75819e92ca6ae5ff004bc1351e4fb72f72bb1bebaddc52cbf56a4e8541b45407",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753991579,
      "headline": "CoreWeave, Arm Holdings, AbbVie: Trending Tickers",
      "id": 136160932,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "CoreWeave (CRWV) stock is in focus after Citigroup upgraded it to Buy and Morgan Stanley lifted its price target. Arm Holdings (ARM) stock is under pressure after the company issued a lower-than-expected profit outlook. AbbVie (ABBV) raised its full-year profit forecast and is facing pressure from President Trump over drug prices. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=75819e92ca6ae5ff004bc1351e4fb72f72bb1bebaddc52cbf56a4e8541b45407"
    }
  },
  {
    "ts": null,
    "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
    "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
    "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753986626,
      "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
      "id": 136160873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
      "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64"
    }
  },
  {
    "ts": null,
    "headline": "Trump demands largest pharma companies slash US drug prices",
    "summary": "(Bloomberg) -- President Donald Trump sent letters to 17 of the world’s largest pharmaceutical companies — including Eli Lilly & Co., Novo Nordisk A/S and Pfizer Inc. — insisting they slash their US prices on new drugs to the lowest amount paid by certain other countries.Most Read from BloombergThe World’s Data Center Capital Has Residents SurroundedAn Abandoned Art-Deco Landmark in Buffalo Awaits RevivalWe Should All Be Biking Along the BeachBudapest’s Most Historic Site Gets a Controversial Re",
    "url": "https://finnhub.io/api/news?id=292aa5d0e8c41af62ddead7ad247376e84410f5a02b83d2a1a0bbf469f796efb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753985112,
      "headline": "Trump demands largest pharma companies slash US drug prices",
      "id": 136160875,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- President Donald Trump sent letters to 17 of the world’s largest pharmaceutical companies — including Eli Lilly & Co., Novo Nordisk A/S and Pfizer Inc. — insisting they slash their US prices on new drugs to the lowest amount paid by certain other countries.Most Read from BloombergThe World’s Data Center Capital Has Residents SurroundedAn Abandoned Art-Deco Landmark in Buffalo Awaits RevivalWe Should All Be Biking Along the BeachBudapest’s Most Historic Site Gets a Controversial Re",
      "url": "https://finnhub.io/api/news?id=292aa5d0e8c41af62ddead7ad247376e84410f5a02b83d2a1a0bbf469f796efb"
    }
  },
  {
    "ts": null,
    "headline": "In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A",
    "summary": "A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place significant bets on psychedelic research.",
    "url": "https://finnhub.io/api/news?id=6b02a9fd74b507814c074d8f97e84d633ccadda1ecbb4d341ac3fc8044dbfacb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753981080,
      "headline": "In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A",
      "id": 136160935,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place significant bets on psychedelic research.",
      "url": "https://finnhub.io/api/news?id=6b02a9fd74b507814c074d8f97e84d633ccadda1ecbb4d341ac3fc8044dbfacb"
    }
  },
  {
    "ts": null,
    "headline": "TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales",
    "summary": "TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.",
    "url": "https://finnhub.io/api/news?id=b42ff2736329986f8a6a8900221a35eb8a538ecbc021c2318d76710ad9740645",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753979880,
      "headline": "TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales",
      "id": 136160913,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.",
      "url": "https://finnhub.io/api/news?id=b42ff2736329986f8a6a8900221a35eb8a538ecbc021c2318d76710ad9740645"
    }
  },
  {
    "ts": null,
    "headline": "Arm Holdings slips on guidance, AbbVie Q2 beat, Bristol-Myers outlook",
    "summary": "Market Catalysts host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Arm Holdings (ARM) shares slide after the company posted weaker-than-expected guidance, with the CEO confirming plans to begin producing its own chips. AbbVie (ABBV) stock jumps after topping earnings expectations and raising guidance. Bristol-Myers Squibb (BMY) lowered its earnings outlook due to a BioNTech (BNTX) partnership-related charge but lifted revenue guidance on strength across its product portfolio. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=c7c520a2fe0b5295c105057369c7cfca8e4769a250a2c81e4898c10917ce7a6e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753978732,
      "headline": "Arm Holdings slips on guidance, AbbVie Q2 beat, Bristol-Myers outlook",
      "id": 136155117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Market Catalysts host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Arm Holdings (ARM) shares slide after the company posted weaker-than-expected guidance, with the CEO confirming plans to begin producing its own chips. AbbVie (ABBV) stock jumps after topping earnings expectations and raising guidance. Bristol-Myers Squibb (BMY) lowered its earnings outlook due to a BioNTech (BNTX) partnership-related charge but lifted revenue guidance on strength across its product portfolio. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=c7c520a2fe0b5295c105057369c7cfca8e4769a250a2c81e4898c10917ce7a6e"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View",
    "summary": "ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.",
    "url": "https://finnhub.io/api/news?id=696c72dc71aabbbec36656fd46ded06ed7ce669ad6466edc0fba483ce7ae8c52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753978500,
      "headline": "AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View",
      "id": 136160914,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.",
      "url": "https://finnhub.io/api/news?id=696c72dc71aabbbec36656fd46ded06ed7ce669ad6466edc0fba483ce7ae8c52"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier",
    "summary": "AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23. Global net revenues from the immunology portfolio were $7.63 billion, up 9.5% (+9.2% on an operational basis), including-Skyrizi sales increased 62.2% (+61.8%) to $4.42 billion; Rinvoq s",
    "url": "https://finnhub.io/api/news?id=0b3f3d8dccced247b61f909478f8214dfb485622cda7e902946884cb65ac6ff6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753975136,
      "headline": "AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier",
      "id": 136155118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23. Global net revenues from the immunology portfolio were $7.63 billion, up 9.5% (+9.2% on an operational basis), including-Skyrizi sales increased 62.2% (+61.8%) to $4.42 billion; Rinvoq s",
      "url": "https://finnhub.io/api/news?id=0b3f3d8dccced247b61f909478f8214dfb485622cda7e902946884cb65ac6ff6"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Q2 2025 Earnings Call Transcript",
    "summary": "AbbVie Inc. (NYSE:ABBV) Q2 2025 Earnings Conference Call July 31, 2025 9:00 AM ETCompany ParticipantsElizabeth Shea - Senior Vice President of Investor...",
    "url": "https://finnhub.io/api/news?id=a2f6cbe04cf7aec51c7703480cfb2de53264ab5ee04b6aeaa17f09c68105e0bc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753974828,
      "headline": "AbbVie Inc. (ABBV) Q2 2025 Earnings Call Transcript",
      "id": 136157254,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. (NYSE:ABBV) Q2 2025 Earnings Conference Call July 31, 2025 9:00 AM ETCompany ParticipantsElizabeth Shea - Senior Vice President of Investor...",
      "url": "https://finnhub.io/api/news?id=a2f6cbe04cf7aec51c7703480cfb2de53264ab5ee04b6aeaa17f09c68105e0bc"
    }
  },
  {
    "ts": null,
    "headline": "PCE Comes in Warmer Than Expected",
    "summary": "PCE Comes in Warmer Than Expected.",
    "url": "https://finnhub.io/api/news?id=1ca45a09932eae527f2336d5e09c3507eca1f8ed0fa96a535a7ff1142a8dad69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753974480,
      "headline": "PCE Comes in Warmer Than Expected",
      "id": 136155303,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "PCE Comes in Warmer Than Expected.",
      "url": "https://finnhub.io/api/news?id=1ca45a09932eae527f2336d5e09c3507eca1f8ed0fa96a535a7ff1142a8dad69"
    }
  },
  {
    "ts": null,
    "headline": "Economy Heating Up on PCE for June",
    "summary": "Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.",
    "url": "https://finnhub.io/api/news?id=1f9132f77d9ef9cec840390c58ca99a40eb0245409cda9055d2f96c3dd12d452",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753973040,
      "headline": "Economy Heating Up on PCE for June",
      "id": 136155105,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.",
      "url": "https://finnhub.io/api/news?id=1f9132f77d9ef9cec840390c58ca99a40eb0245409cda9055d2f96c3dd12d452"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "summary": "While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finnhub.io/api/news?id=008f17d42b321da1701bf81390501ddeb2e70d065da81f544ea0c140e6b4594e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753972203,
      "headline": "AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates",
      "id": 136155120,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
      "url": "https://finnhub.io/api/news?id=008f17d42b321da1701bf81390501ddeb2e70d065da81f544ea0c140e6b4594e"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Lifts Full-Year Guidance as Immunology Drugs Drive Quarterly Beat",
    "summary": "AbbVie (ABBV) raised its full-year outlook on Thursday as the biopharmaceutical company recorded sec",
    "url": "https://finnhub.io/api/news?id=d8655dff9834f18120b7cb01e130728072f3a2c7fe9442d7b90667a83209f2f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753972139,
      "headline": "AbbVie Lifts Full-Year Guidance as Immunology Drugs Drive Quarterly Beat",
      "id": 136155121,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) raised its full-year outlook on Thursday as the biopharmaceutical company recorded sec",
      "url": "https://finnhub.io/api/news?id=d8655dff9834f18120b7cb01e130728072f3a2c7fe9442d7b90667a83209f2f1"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal",
    "summary": "(Bloomberg) -- AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people familiar with the matter, highlighting growing interest in a controversial field of medicine that’s starting to gain wider acceptance.Most Read from BloombergThe World’s Data Center Capital Has Residents SurroundedAn Abandoned Art-Deco Landmark in Buffalo Awaits RevivalWe Should All Be Biking Along the BeachBudapest’s Most Historic Site Gets a Controversial Rebu",
    "url": "https://finnhub.io/api/news?id=5dc654f06ec0244924b669b7a03d3253acda6bfb144cdd2a9e94902990d2499c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753968585,
      "headline": "AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal",
      "id": 136155122,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people familiar with the matter, highlighting growing interest in a controversial field of medicine that’s starting to gain wider acceptance.Most Read from BloombergThe World’s Data Center Capital Has Residents SurroundedAn Abandoned Art-Deco Landmark in Buffalo Awaits RevivalWe Should All Be Biking Along the BeachBudapest’s Most Historic Site Gets a Controversial Rebu",
      "url": "https://finnhub.io/api/news?id=5dc654f06ec0244924b669b7a03d3253acda6bfb144cdd2a9e94902990d2499c"
    }
  },
  {
    "ts": null,
    "headline": "Investors Digest Fed's Preferred Inflation Gauge, Driving Premarket Gains for US Equity Futures",
    "summary": "US equity futures were up ahead of Thursday's opening bell as traders digested a key inflation repor",
    "url": "https://finnhub.io/api/news?id=a2b24cf327ed9502b3143f38e308ce4d2205431a154d84dfc8922a0b523639b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753966844,
      "headline": "Investors Digest Fed's Preferred Inflation Gauge, Driving Premarket Gains for US Equity Futures",
      "id": 136151760,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "US equity futures were up ahead of Thursday's opening bell as traders digested a key inflation repor",
      "url": "https://finnhub.io/api/news?id=a2b24cf327ed9502b3143f38e308ce4d2205431a154d84dfc8922a0b523639b8"
    }
  },
  {
    "ts": null,
    "headline": "Sales of Skyrizi, Rinvoq Help AbbVie Results Top Wall Street’s Forecasts",
    "summary": "AbbVie’s beat Wall Street’s estimates for its top- and bottom-lines in the second quarter, boosted by sales of Skyrizi and Rinvoq.",
    "url": "https://finnhub.io/api/news?id=f8a09dfe8db72941936a2e8667d391e097414dbf6a645dec01c149cd864cdf1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753966800,
      "headline": "Sales of Skyrizi, Rinvoq Help AbbVie Results Top Wall Street’s Forecasts",
      "id": 136155123,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie’s beat Wall Street’s estimates for its top- and bottom-lines in the second quarter, boosted by sales of Skyrizi and Rinvoq.",
      "url": "https://finnhub.io/api/news?id=f8a09dfe8db72941936a2e8667d391e097414dbf6a645dec01c149cd864cdf1e"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates",
    "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of +2.77% and +2.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=282f8887f0427f7d5c12e37b325e294493cc24023f8a79c228b7f83e56b1bb57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753966501,
      "headline": "AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates",
      "id": 136155124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of +2.77% and +2.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=282f8887f0427f7d5c12e37b325e294493cc24023f8a79c228b7f83e56b1bb57"
    }
  },
  {
    "ts": null,
    "headline": "Five Things That Might Move July 2025's Job Report",
    "summary": "July's jobs report reveals mixed signals. Discover key sectors with growth momentum and risks in labor trends to strategically position your portfolio.",
    "url": "https://finnhub.io/api/news?id=bf9966f57ad47866f0faa025eb017f7b67cc45162595361c4dfaf33069cdca8c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753965389,
      "headline": "Five Things That Might Move July 2025's Job Report",
      "id": 136154933,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1139664297/image_1139664297.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "July's jobs report reveals mixed signals. Discover key sectors with growth momentum and risks in labor trends to strategically position your portfolio.",
      "url": "https://finnhub.io/api/news?id=bf9966f57ad47866f0faa025eb017f7b67cc45162595361c4dfaf33069cdca8c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie raises full-year earnings guidance amid acquisition drive",
    "summary": "Investing.com - AbbVie has lifted its full-year earnings forecast despite expenses related to its ongoing acquisition drive, sending shares higher in premarket U.S. trading on Thursday.",
    "url": "https://finnhub.io/api/news?id=1de4c37e64db31a8d5266a88106e9637198dd3d9a0413bd7f657f1667e2e413c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753965284,
      "headline": "AbbVie raises full-year earnings guidance amid acquisition drive",
      "id": 136151792,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investing.com - AbbVie has lifted its full-year earnings forecast despite expenses related to its ongoing acquisition drive, sending shares higher in premarket U.S. trading on Thursday.",
      "url": "https://finnhub.io/api/news?id=1de4c37e64db31a8d5266a88106e9637198dd3d9a0413bd7f657f1667e2e413c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Pops After Earnings. What’s Driving Shares Higher.",
    "summary": "AbbVie  hiked its full-year outlook on the back of better-than-expected earnings early Thursday, sending shares of the drugmaker up in premarket trading.  Shares were up 5.1% to $199.45 in premarket trading immediately after the report.",
    "url": "https://finnhub.io/api/news?id=771e3b5ddba719be14ac6bb8ce9b8a3896513c8d1f92ef27184ea3770a9a7fe6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753964940,
      "headline": "AbbVie Stock Pops After Earnings. What’s Driving Shares Higher.",
      "id": 136151793,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie  hiked its full-year outlook on the back of better-than-expected earnings early Thursday, sending shares of the drugmaker up in premarket trading.  Shares were up 5.1% to $199.45 in premarket trading immediately after the report.",
      "url": "https://finnhub.io/api/news?id=771e3b5ddba719be14ac6bb8ce9b8a3896513c8d1f92ef27184ea3770a9a7fe6"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie in Talks to Buy Gilgamesh Pharmaceuticals for $1 Billion",
    "summary": "$1 billion deal discussions reported by Bloomberg",
    "url": "https://finnhub.io/api/news?id=f48ec06b84acab489d17e3869d64e40ab207551add7d60f8cb091d9fa772c8ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753964079,
      "headline": "AbbVie in Talks to Buy Gilgamesh Pharmaceuticals for $1 Billion",
      "id": 136151794,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "$1 billion deal discussions reported by Bloomberg",
      "url": "https://finnhub.io/api/news?id=f48ec06b84acab489d17e3869d64e40ab207551add7d60f8cb091d9fa772c8ad"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s (NYSE:ABBV) Q2: Beats On Revenue",
    "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q2 CY2025, with sales up 6.6% year on year to $15.42 billion. Its non-GAAP profit of $2.97 per share was 2.1% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=956a6aa32f7a61c4503a25a64db3c76cab18e7c47d1232e8fe677f423667835d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753963822,
      "headline": "AbbVie’s (NYSE:ABBV) Q2: Beats On Revenue",
      "id": 136151795,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q2 CY2025, with sales up 6.6% year on year to $15.42 billion. Its non-GAAP profit of $2.97 per share was 2.1% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=956a6aa32f7a61c4503a25a64db3c76cab18e7c47d1232e8fe677f423667835d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Q2 Earnings Snapshot",
    "summary": "The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $2.89 per share. The drugmaker posted revenue of $15.42 billion in the period, also beating Street forecasts.",
    "url": "https://finnhub.io/api/news?id=b702f623e97957fc96ed59bf3a21b11463032288187a649b3d691cc343f27aad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753962997,
      "headline": "AbbVie: Q2 Earnings Snapshot",
      "id": 136151796,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $2.89 per share. The drugmaker posted revenue of $15.42 billion in the period, also beating Street forecasts.",
      "url": "https://finnhub.io/api/news?id=b702f623e97957fc96ed59bf3a21b11463032288187a649b3d691cc343f27aad"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie lifts profit forecast on strong demand for newer immunology drugs",
    "summary": "AbbVie raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong sales of its newer immunology drugs Skyrizi and Rinvoq. Shares of the drugmaker jumped nearly 6% to $199.70 before the bell. The company is pushing Skyrizi and Rinvoq to counter the drop in sales of arthritis treatment Humira, as the once-bestselling drug faces competition from several cheaper biosimilars that began hitting the U.S. market in 2023.",
    "url": "https://finnhub.io/api/news?id=31dd6bbc5f3ac5147ced1082664f80d010c382192175cfd613b1da5b10c096e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753962705,
      "headline": "AbbVie lifts profit forecast on strong demand for newer immunology drugs",
      "id": 136151797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong sales of its newer immunology drugs Skyrizi and Rinvoq. Shares of the drugmaker jumped nearly 6% to $199.70 before the bell. The company is pushing Skyrizi and Rinvoq to counter the drop in sales of arthritis treatment Humira, as the once-bestselling drug faces competition from several cheaper biosimilars that began hitting the U.S. market in 2023.",
      "url": "https://finnhub.io/api/news?id=31dd6bbc5f3ac5147ced1082664f80d010c382192175cfd613b1da5b10c096e9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Reports Second-Quarter 2025 Financial Results",
    "summary": "AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2025.",
    "url": "https://finnhub.io/api/news?id=2d08b4c8c6ddab9c5ff11ffa0bf3ddbc0eed93450d416e27e57c5683e6a20580",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753962240,
      "headline": "AbbVie Reports Second-Quarter 2025 Financial Results",
      "id": 136151798,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2025.",
      "url": "https://finnhub.io/api/news?id=2d08b4c8c6ddab9c5ff11ffa0bf3ddbc0eed93450d416e27e57c5683e6a20580"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Rise Pre-Bell as Fed Keeps Rates Steady; Key Inflation Report, More Tech Earnings on Deck",
    "summary": "US equity markets were tracking in the green before the opening bell Thursday following the Federal",
    "url": "https://finnhub.io/api/news?id=fada1feee30041f4d7e6d4c48a13a7c345365e18052f60a2eb3fbfc96316c07e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753961500,
      "headline": "Stocks Rise Pre-Bell as Fed Keeps Rates Steady; Key Inflation Report, More Tech Earnings on Deck",
      "id": 136151591,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "US equity markets were tracking in the green before the opening bell Thursday following the Federal",
      "url": "https://finnhub.io/api/news?id=fada1feee30041f4d7e6d4c48a13a7c345365e18052f60a2eb3fbfc96316c07e"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie reports encouraging data from Upadacitinib trial for alopecia areata",
    "summary": "The primary endpoint was met in Study 2, with subjects achieving 80% or above scalp hair coverage at week 24.",
    "url": "https://finnhub.io/api/news?id=241ae4dcbf511d2f80e3c7e1fbf7749a5d738b4c6cceef8f11ee3304502ea184",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753959380,
      "headline": "AbbVie reports encouraging data from Upadacitinib trial for alopecia areata",
      "id": 136151800,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The primary endpoint was met in Study 2, with subjects achieving 80% or above scalp hair coverage at week 24.",
      "url": "https://finnhub.io/api/news?id=241ae4dcbf511d2f80e3c7e1fbf7749a5d738b4c6cceef8f11ee3304502ea184"
    }
  },
  {
    "ts": null,
    "headline": "US stock futures higher after Meta, Microsoft results",
    "summary": "Both companies are part of the so-called Magnificent Seven megacap, influential tech giants.",
    "url": "https://finnhub.io/api/news?id=b1aa538aaee4a91ec26531287d5aef70d39384d36b9b0d54f912b740b4160288",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753956724,
      "headline": "US stock futures higher after Meta, Microsoft results",
      "id": 136151598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Both companies are part of the so-called Magnificent Seven megacap, influential tech giants.",
      "url": "https://finnhub.io/api/news?id=b1aa538aaee4a91ec26531287d5aef70d39384d36b9b0d54f912b740b4160288"
    }
  },
  {
    "ts": null,
    "headline": "Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas",
    "summary": "Discover key insights with the \"Renal Failure - Global Clinical Trials Review, 2025.\" This comprehensive report offers an overview of Renal Failure clinical trials, covering trial numbers, phases, statuses, and sponsor types globally. Stay ahead with data-driven decisions and gain competitive advantage.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Renal Failure - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report pr",
    "url": "https://finnhub.io/api/news?id=7387ca0de66b5f22e1f2c30bda60d37e485fcf2d727def98fb5269bb66488e21",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753955100,
      "headline": "Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas",
      "id": 136151802,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Discover key insights with the \"Renal Failure - Global Clinical Trials Review, 2025.\" This comprehensive report offers an overview of Renal Failure clinical trials, covering trial numbers, phases, statuses, and sponsor types globally. Stay ahead with data-driven decisions and gain competitive advantage.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Renal Failure - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report pr",
      "url": "https://finnhub.io/api/news?id=7387ca0de66b5f22e1f2c30bda60d37e485fcf2d727def98fb5269bb66488e21"
    }
  },
  {
    "ts": null,
    "headline": "Sicca Syndrome (Sjogren) Clinical Trials Market Landscape Report 2025 Featuring Novartis, BMS, ICON, AbbVie, Parexel, Thermo Fisher Scientific, Amgen, Laboratory Corp of America, IQVIA, Syneos Health",
    "summary": "Discover key insights with the \"Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025.\" This comprehensive report offers top-line data on Sicca Syndrome (Sjogren) trials worldwide, covering trial numbers, enrollment, regions, phases, and sponsors. Enhance decision-making and gain a competitive edge.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical",
    "url": "https://finnhub.io/api/news?id=0993e4dc449036d1d6b6c28ed1f6c34e436cbf92c1cd937d4ca518ab043c7c25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753954680,
      "headline": "Sicca Syndrome (Sjogren) Clinical Trials Market Landscape Report 2025 Featuring Novartis, BMS, ICON, AbbVie, Parexel, Thermo Fisher Scientific, Amgen, Laboratory Corp of America, IQVIA, Syneos Health",
      "id": 136151803,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Discover key insights with the \"Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025.\" This comprehensive report offers top-line data on Sicca Syndrome (Sjogren) trials worldwide, covering trial numbers, enrollment, regions, phases, and sponsors. Enhance decision-making and gain a competitive edge.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical",
      "url": "https://finnhub.io/api/news?id=0993e4dc449036d1d6b6c28ed1f6c34e436cbf92c1cd937d4ca518ab043c7c25"
    }
  },
  {
    "ts": null,
    "headline": "Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health",
    "summary": "Discover insights with the \"Glaucoma - Global Clinical Trials Review, 2025.\" This comprehensive report outlines the global scenario of glaucoma clinical trials, offering top-line data by region, country, phase, and sponsor type. Leverage key findings to enhance decision-making and optimize strategies in the competitive clinical trials landscape.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Glaucoma - Global Clinical Trials Review, 2025\" has been added to ResearchAndMarkets.com's offering. The c",
    "url": "https://finnhub.io/api/news?id=c693a38a686efe72f5da5591f613698427afe75985b2c1bc3721fa2d3897d600",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753954020,
      "headline": "Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health",
      "id": 136151804,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Discover insights with the \"Glaucoma - Global Clinical Trials Review, 2025.\" This comprehensive report outlines the global scenario of glaucoma clinical trials, offering top-line data by region, country, phase, and sponsor type. Leverage key findings to enhance decision-making and optimize strategies in the competitive clinical trials landscape.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Glaucoma - Global Clinical Trials Review, 2025\" has been added to ResearchAndMarkets.com's offering. The c",
      "url": "https://finnhub.io/api/news?id=c693a38a686efe72f5da5591f613698427afe75985b2c1bc3721fa2d3897d600"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: raises FY EPS target",
    "summary": "Announcing another exceptional quarter thanks to the strong performance of its diversified growth platform, AbbVie has raised its adjusted EPS guidance range for 2025 from $11.67-11.87 to...",
    "url": "https://finnhub.io/api/news?id=ac5ddf8eac91212a050e28257dd74480aef0ca4b23461dffc5ba1d182458651a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753952718,
      "headline": "AbbVie: raises FY EPS target",
      "id": 136151498,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Announcing another exceptional quarter thanks to the strong performance of its diversified growth platform, AbbVie has raised its adjusted EPS guidance range for 2025 from $11.67-11.87 to...",
      "url": "https://finnhub.io/api/news?id=ac5ddf8eac91212a050e28257dd74480aef0ca4b23461dffc5ba1d182458651a"
    }
  },
  {
    "ts": null,
    "headline": "The Fed Isn't Sure About The Economy Anymore",
    "summary": "Explore the latest FOMC insights on US growth, inflation, and rate cut expectations. Discover why defensives remain key amid market gains.",
    "url": "https://finnhub.io/api/news?id=b394e924f7defb6e09bf9db475c7c510704f1186a3dc1b9d93ffce114d712a14",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753951541,
      "headline": "The Fed Isn't Sure About The Economy Anymore",
      "id": 136151416,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1308151210/image_1308151210.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Explore the latest FOMC insights on US growth, inflation, and rate cut expectations. Discover why defensives remain key amid market gains.",
      "url": "https://finnhub.io/api/news?id=b394e924f7defb6e09bf9db475c7c510704f1186a3dc1b9d93ffce114d712a14"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales",
    "summary": "AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales",
    "url": "https://finnhub.io/api/news?id=8c20947ecd34e4f7ef7199f4634f9c37eba6382978bf4de5796386f6039a5063",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753950660,
      "headline": "AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales",
      "id": 136167913,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales",
      "url": "https://finnhub.io/api/news?id=8c20947ecd34e4f7ef7199f4634f9c37eba6382978bf4de5796386f6039a5063"
    }
  },
  {
    "ts": null,
    "headline": "Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Report 2025: Global Trends, Revenue, and Market Dynamics",
    "summary": "The global IBS and IBD therapeutics market is set to grow from $33.3 billion in 2025 to $52.6 billion by 2030, at a 9.6% CAGR. The report analyzes market trends, key players, and regional impact, offering insights into drug classes and business strategies of industry leaders like AbbVie and Amgen. Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Ir",
    "url": "https://finnhub.io/api/news?id=39f4af6403ea85af6b158ce0e988ed79f5a11e547aad05825448704ed30662f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753949520,
      "headline": "Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Report 2025: Global Trends, Revenue, and Market Dynamics",
      "id": 136148872,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The global IBS and IBD therapeutics market is set to grow from $33.3 billion in 2025 to $52.6 billion by 2030, at a 9.6% CAGR. The report analyzes market trends, key players, and regional impact, offering insights into drug classes and business strategies of industry leaders like AbbVie and Amgen. Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Ir",
      "url": "https://finnhub.io/api/news?id=39f4af6403ea85af6b158ce0e988ed79f5a11e547aad05825448704ed30662f7"
    }
  }
]